ReviewEndocrinology, diabetes & metabolism2020
The metabolic basis of nonalcoholic steatohepatitis.
Review in Endocrinology, diabetes & metabolism, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 4 syntheses or guidelines pooled it, 84 citations in OpenAlex.
- An updated systematic review and meta-analysis: correlation between circulating plasminogen activator inhibitor-1 levels and metabolic dysfunction-associated steatotic liver disease.BMC gastroenterology · 2025Pooled it
- Association between non-alcoholic fatty liver disease and risk of sarcopenia: a systematic review and meta-analysis.BMJ open · 2024Pooled it
- Hepatoprotection of Probiotics Against Non-Alcoholic Fatty Liver DiseaseFrontiers in nutrition · 2022Pooled it
- Nonalcoholic fatty liver disease as a metabolic disease in humans: A literature review.Diabetes, obesity & metabolism · 2021Pooled it
- Bioactive glasses-mediated ion therapy ameliorates hepatic osteodystrophy by reprogramming the liver-bone axis.Bioactive materials · 2027Article
- Dynamic Alterations of BMP9 in NAFLD: A Novel Hepatokine Marker of Metabolic Dysfunction and Disease Severity.Diabetes, metabolic syndrome and obesity : targets and therapy · 2026Article
- Article
- Impact of Levothyroxine on Progression to and Complications of Cirrhosis in MASH.Digestive diseases and sciences · 2025Article
- Perspectives on whole body and tissue-specific metabolic flexibility and implications in cardiometabolic diseases.Cell reports. Medicine · 2025Review
- Different formulations of semaglutide and oxidative stress in subjects with type 2 diabetes and MASLD: an open-label, real-life study.Acta diabetologica · 2025Article
- Muscle Strength and Cardiovascular Health in MASLD: A Prospective Study.Medicina (Kaunas, Lithuania) · 2025Article
- Reduced Intra- and Extracellular Circulating Postprandial Lysosomal Acid Lipase Activity in Patients with MASLD.Metabolites · 2024Article
- Analysis of Quality Intima-Media Thickness and Quantitative Artery Stiffness technologies on non-alcoholic fatty liver disease: a study on carotid artery structure, elasticity, and influential factors in patients.Quantitative imaging in medicine and surgery · 2024Article
- Fat burning capacity in a mixed macronutrient meal protocol does not reflect metabolic flexibility in women who are overweight or obese.medRxiv : the preprint server for health sciences · 2024Article
- Non-Invasive Assessment of Metabolic Dysfunction-Associated Steatotic Liver Disease in Adolescents with Severe Obesity; Patient Characteristics and Association with Leptin-A Cross-Sectional Overview of Baseline Data from a RCT.Children (Basel, Switzerland) · 2024Article
- Article
- Dietary inflammatory index is associated with metabolic dysfunction-associated fatty liver disease among United States adults.Frontiers in nutrition · 2024Article
- Histidine-rich glycoprotein in metabolic dysfunction-associated steatohepatitis-related disease progression and liver carcinogenesis.Frontiers in immunology · 2024Article
- Cell-type specific role of autophagy in the liver and its implications in non-alcoholic fatty liver disease.World journal of hepatology · 2023Article
- Isotope Labeling and Biochemical Assessment of Liver-Triacylglycerol in Patients with Different Levels of Histologically-Graded Liver Disease.The Journal of nutrition · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nonalcoholic fatty liver disease (NAFLD) is a major cause of chronic liver disease and is associated with significant morbidity and mortality worldwide, with a high incidence in Western countries and non-Western countries that have adopted a Western diet. NAFLD is commonly associated with components of the metabolic syndrome, type 2 diabetes mellitus and cardiovascular disease, suggesting a common mechanistic basis. An inability to metabolically handle free fatty acid overload-metabolic inflexibility-constitutes a core node for NAFLD pathogenesis, with resulting lipotoxicity, mitochondrial dysfunction and cellular stress leading to inflammation, apoptosis and fibrogenesis. These responses can lead to the histological phenotype of nonalcoholic steatohepatitis (NASH) with varying degrees of fibrosis, which can progress to cirrhosis. This perspective review describes the key cellular and molecular mechanisms of NAFLD and NASH, namely an excessive burden of carbohydrates and fatty acids that contribute to lipotoxicity resulting in hepatocellular injury and fibrogenesis. Understanding the extrahepatic dysmetabolic contributors to NASH is crucial for the development of safe, effective and durable treatment approaches for this increasingly common disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.